# dapsone

### notes
+ prescription under medical supervision
### therapeutic action

+ sulfone antibacterial
+ antileprotic

### indications
+ prophylaxis of toxoplasmosis and pneumocystosis
+ treatment of pneumocystosis
+ paucibacillary and multibacillary leprosy, in combination with other antileprotics

### presentation
+ 25 mg, 50 mg and 100 mg tablets

### dosage
+ prophylaxis of pneumocystosis only
child: 2 mg/kg once daily, without exceeding 100 mg/day
adult: 100 mg once daily
+ prophylaxis of toxoplasmosis and pneumocystosis
child: 2 mg/kg once daily, without exceeding 25 mg/day (in combination with pyrimethamine 1 mg/kg
once daily + folinic acid 10 mg/week)
adult:
    - 50 mg once daily (in combination with pyrimethamine 50 mg/week + folinic acid 25 to 30 mg/week)
    - or 200 mg once weekly (in combination with pyrimethamine 75 mg/week + folinic acid 25 to
30 mg/week)
+ treatment of pneumocystosis (in combination with 15 mg/kg/day of trimethoprime)
child: 2 mg/kg once daily, without exceeding 100 mg/day
adult: 100 mg once daily
+ paucibacillary and multibacillary leprosy
child under 10 years: 25 mg once daily
child from 10 to 14 years: 50 mg once daily
adult: 100 mg once daily

### duration
+ prophylaxis of toxoplasmosis and pneumocystosis: as long as necessary; treatment of pneumocystosis: 21 days; paucibacillary leprosy: 6 months; multibacillary leprosy: 12 months

### contra-indications, adverse effects, precautions
+ do not administer to patients with allergy to sulfones or severe anaemia (first treat anaemia).
+ administer with caution to patients with renal or hepatic impairment.
+ may cause: haemolytic anaemia in patients with g6pd deficiency, dose-related haemolytic anaemia, neutropenia, methaemoglobinaemia, pruritus, rash, gastrointestinal disturbances, peripheral neuropathies, agranulocytosis; hypersensitivity reactions during the first month of treatment (fever, jaundice, hepatitis, adenopathy, exfoliative dermatitis, etc.) requiring permanent discontinuation of treatment.
+ monitor blood count and transaminases if possible.
+ do not administer simultaneously with didanosine: administer each drug 2 hours apart.
+ monitor combination with zidovudine (increased haematological toxicity).
+ *pregnancy*: no contra-indication
+ *breast-feeding*: no contra-indication

### remarks
+ for the treatment of leprosy, dapsone must always be used in combination with rifampicin (paucibacillary leprosy) or rifampicin + clofazimine (multibacillary leprosy) in order to avoid the emergence of resistance.
+ storage: below 25Â°c